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ABSTRACT
Due to the increasing incidence of cancer diagnoses and lack of validated screenings for most
types of cancer, cancer researchers continue to look for ways to improve cancer screening
particularly for cancers that are difficult to detect early. One early detection technology being
researched is blood-based testing looking for the presence of DNA from tumor cells, circulating
tumor DNA (ctDNA). With any new cancer screening test there is a need to understand how
participants respond, socially and psychologically, to abnormal results. Participants in
Geisinger’s DETECT study of a ctDNA test, CancerSEEK, who received positive ctDNA blood
test results and opted to undergo a PET-CT scan, were interviewed to assess psychosocial
outcomes of true positive and false positive blood test results. Qualitative data analysis of
interviews of participants with true positive and false positive results using Atlas.ti identified 16
major themes. Results of the qualitative analysis revealed some differences between the negative
and positive PET-CT groups. However, most participants, in both groups, reported a positive
experience with the DETECT study and would recommend it to others. Results of the study
suggest that the psychosocial outcomes associated with ctDNA-based cancer screening tests
should continue to be explored in-depth to provide sufficient evidence for future usage.
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INTRODUCTION
Cancer is defined as uncontrolled cell growth; malignant cells grow and divide rapidly
leading to a diagnosis that is either localized or metastasized throughout tissues of the body.
Cancer cells have six main features that distinguish them from healthy cells: independence of
external growth signals, insensitivity to external anti-growth signals, ability to avoid apoptosis,
ability to duplicate indeterminately, ability to activate angiogenesis and vascularize, and ability
to attack tissues and create secondary tumors (Hanahan & Weinberg, 2000). Cancer is the second
leading cause of death in the United States and each year the number of diagnoses and deaths
increase worldwide. The chance to develop cancer depends on an individual’s exposure, medical
history, and genetic predisposition. The lifetime risk for a male to develop an invasive cancer is
42%, whereas for women it is 38%. While there has been a consistent decline in the death rate
from cancer, by 1.4% in women and 1.8% in men annually from 2007 to 2016, it remains a
serious public health concern. An estimated 1.7 million new cancer cases will arise in 2019 alone
(Siegel et al., 2019).
Recommended Screening Guidelines, Risk Reduction Benefits, and Psychosocial Outcomes
for Existing Cancer Screening Modalities
Several screening tests have been found to reduce cancer morbidity and mortality rates.
Many organizations provide evidence-based recommendations about cancer screenings;
however, these recommendations vary, making these preventive services more difficult for
patients and providers to navigate. It is important to assess the societal and individual impact of
these screenings in an effort to promote adherence. Adherence to screening recommendations
provides the benefit of detecting cancer at earlier stages; nonadherence diminishes this benefit.
When considering reasons for nonadherence, psychosocial harms of the screenings should be
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explored. There is significant evidence of anxiety produced by cancer screening methods,
especially when false positive results are the outcome (Brodersen & Siersma, 2013; Lipkus et al.,
2000; Toft et al., 2019). The recommended screening guidelines, risk reduction benefits, and
associated psychosocial harms are outlined for the following cancers: breast, colorectal, and
lung.
Breast Cancer
The United States Preventive Services Task Force (USPSTF) recommends biennial
mammography screening for women aged 50 to 74 years to maximize screening benefits. The
USPSTF specifies that these guidelines are appropriate for average-risk women, who are at the
general population risk to develop cancer. Prior to this, between ages 40 to 49, the decision to
begin screening is on an individual basis. Lastly, the USPSTF provides no recommendations for
screening women aged 75 and older (Siu et al., 2016). In contrast with the USPSTF, the National
Comprehensive Cancer Network (NCCN) and other professional societies recommend annual
mammography screening beginning at age 40 in average-risk women. Women who begin
mammography screening in their 40s benefit from a reduction in breast cancer mortality. Early
detection of breast cancer also leads to less aggressive treatment regimens and associated
morbidities. The screening benefits outweigh the psychosocial harms associated with
mammography, like anxiety due to false positive results and overdiagnoses. NCCN also
addresses screening recommendations for women at increased risk of breast cancer (NCCN
Guidelines Version 1.2019 Breast Cancer Screening and Diagnosis, 2019). Notably, the USPSTF
does not provide screening recommendations for this group of high-risk women.
Women receiving false positive results report negative psychosocial harms such as
breast-cancer specific worry, concern impacting mood and daily routines, lower cognitive
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functioning, lower energy levels, and increased depression. Additionally, follow-up testing with
negative results can cause persistent anxiety, continued breast-cancer specific worry, and distress
for patients (Nelson et al., 2016). One study evaluated 12 psychosocial outcomes among 454
women with abnormal findings on mammography screening, using the Consequences of
Screening in Breast Cancer Questionnaire. For every woman recruited with an abnormal finding,
either true or false positive, two were enrolled that received normal mammogram screening
results. Women with false positive results reported changes in existential values and inner
calmness which were equivalent to responses reported by women with a diagnosis of breast
cancer. In addition, women continuing to receive false positive results post-cancer diagnosis
reported more negative psychosocial harms than women with normal mammogram screening
results (Brodersen & Siersma, 2013).
Colorectal Cancer
To reduce colorectal cancer incidence and mortality, the USPSTF recommends screening
in average-risk adults starting at age 50 years and continuing until age 75 years. The decision to
screen for colorectal cancer in adults aged 76 to 85 is an individual one. Screening strategies
include stool-based, direct visualization and serology tests, each with unique advantages and
limitations (US Preventive Services Task Force, 2016). NCCN recommends starting screening
earlier in adults at increased risk due to family history of cancer or pathogenic variants in
colorectal cancer susceptibility genes. Shorter screening intervals are recommended for those at
increased risk, compared to average-risk individuals who present for colonoscopy every 5-10
years (NCCN Guidelines Version 2.2019 Colorectal Cancer Screening, 2019).
Reported harms include unnecessary invasive follow-up testing for patients at low-risk
and increased rates of anxiety, discomfort, and morbidity (US Preventive Services Task Force,
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2016). One study assessed the psychosocial harms of receiving false positive screening results
from an immunochemical fecal occult blood test (iFOBT), by interviewing 16 participants about
their false positive results. Four main themes emerged: anxiety, discomfort, different selfperception/behavior, and views on active participation in screening. False positive results led to
prolonged feelings of anxiety among some participants, resulting in an increase in existing
anxiety and psychological impairments. Individuals may feel discomfort during a screening
procedure, their self-perception may change upon experiencing the process, and they may
demonstrate hesitancy towards diagnostic screening methods in the future (Toft et al., 2019).
Lung Cancer
The USPSTF recommends annual low-dose computed tomography (LDCT) for
individuals who have a 30 pack-year smoking history and currently smoke or have quit within
the past 15 years, and are aged 55 to 80. Annual LDCT screening serves as a benefit for high-risk
individuals and can prevent lung cancer-related mortality. Lung cancer screening can be
associated with negative psychosocial outcomes due to false positive results, false negative
results, incidental findings, overdiagnosis, and increased radiation exposure leading to cancer
(Moyer et al., 2014).
NCCN recommends LDCT testing after performing extensive risk assessment and
categorizing risk status (high, moderate, or low-risk). Benefits of LDCT testing include
decreased lung cancer mortality and discovery of other crucial health risks. A major benefit
suggests an increase in quality of life by pursuing lung cancer screening, leading to the
following: less morbidity related to the disease and treatment, aiding in a healthy lifestyle, and
lessening anxiety/psychosocial harms. Psychosocial harms noted by NCCN include a decrease in
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quality of life and anxiety of test findings (NCCN Guidelines Version 1.2020 Lung Cancer
Screening, 2020).
Future Directions for Cancer Screening with ctDNA
Of the early detection technologies being researched, one of increasing interest is a
blood-based testing looking for the presence of DNA from tumor cells. In contrast to many
current cancer screenings, ctDNA-based screening offers an opportunity to screen for multiple
cancers at once, including cancers for which no standard-of-care screenings exist, such as
pancreatic and ovarian cancer. While a benefit of ctDNA-based cancer screening is that it is
minimally invasive, requiring only a blood test, the psychosocial outcomes of abnormal ctDNA
screening are unknown. As with any new screening modality, investigation into the psychosocial
outcomes of abnormal results is important in understanding what may influence adherence, how
it should be implemented clinically, and how it could positively or negatively impact care.
Historical Background of ctDNA
Documentation of the presence of circulating tumor cells goes back to the late 1800s
when it was first observed in the blood of cancer patients (Neumann et al., 2018). Further
evidence of the possibility of tumor DNA circulating in the blood came from a 1977 study
comparing the level of free DNA in the serum of patients with different types of cancers to study
participants without cancer (Leon et al., 1977). It was found that the levels of free DNA were
increased in patients with cancer as compared to those without cancer; further differentiation
found that those with metastatic cancers had significantly higher free DNA levels than those
whose cancer was in situ. Significant decreases in the free DNA levels were found in the cancer
patients who saw clinical improvements, like reduced tumor size, compared to patients who did
not respond to cancer treatments and whose DNA levels were maintained throughout the study.
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While the source of the additional free DNA was not fully understood in the study, the
correlation of free DNA levels with the presence of cancer was indicative of some contribution
of the tumor DNA to free DNA levels (Leon et al., 1977). More recently, expanded use of cellfree DNA (cfDNA) for prenatal screening provided further evidence of tumor DNA circulating
in the bloodstream through cfDNA results that were discordant with the fetal karyotype. The
discordance was explained by the presence of maternal malignancy during pregnancy (Bianchi et
al., 2015).
Liquid Biopsy
A liquid biopsy is the analysis of tumor-derived components found in the bloodstream;
these components include a combination of whole circulating tumor cells (CTCs), circulating
tumor DNA (ctDNA), RNA, proteins, and lipids that are shed from a tumor as apoptosis occurs
(Palmirotta et al., 2018). The CTCs component of liquid biopsy are a stable, viable group of cells
that can be purified from blood or particles on the surface of cells that differentiate them from
typical blood cells. The ctDNA component is derived from lysed CTCs and consists of tiny
fragments of free nucleic acids no longer associated with a cell (Olivi et al., 2014). Since the
initial evidence of tumor analytes circulating in the blood, the use of liquid biopsy technology to
detect these analytes has expanded to possibly become a fast, noninvasive, and low cost way of
detecting cancer and monitoring disease status in response to treatment. It is believed that liquid
biopsy circumvents challenges from biopsy of inaccessible tumors and biopsies that do not give a
comprehensive picture of the tumor make up given metastasis or heterogeneity throughout the
tumor tissue (Neumann et al., 2018). Proof of principle of how ctDNA works was established in
a 2018 study done by Cohen et al., that used the ctDNA liquid biopsy, CancerSEEK, to
successfully detect 70% of cancers that had already been clinically diagnosed. The specificity of
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this liquid biopsy was more than 99% across the eight cancer types that it was used to confirm
diagnosis in.
Benefits and Limitations of ctDNA Testing
ctDNA analysis has the potential to address a limitation of traditional tumor tissue biopsy
- the oversight of possible driver mutations given the limited scope of biopsy and the
heterogeneity of tumor tissue. This limitation results in a lack of information on the tumor
profile. There is also the limitation of tumor tissue not always being accessible for biopsy or
metastasis making a biopsy of all tumor tissue difficult (Stewart et al., 2018). Potential areas of
application for ctDNA include tumor diagnosis to detect residual tumor after surgery, cancer
treatment response and follow-up, and the molecular evolution of tumors resistant to treatment
(Neumann et al., 2018). Despite these benefits, some studies have shown a rate of discordance
between ctDNA assays and tumor testing. This could be the result of what cells are released from
the tumor, where the tumor is, what barriers are present that prevent cells from entering the
circulatory system and insufficient amounts of ctDNA being present in the blood sample. What
tumor tissue testing shows, that ctDNA assays can fail to reveal, is a full picture of new cell
variants within the tumor (Merker et al., 2018). Early detection of cancer is complicated with
liquid biopsy by the mutation load being minimal or below the level of detection in early cancer
stages. The proportion of ctDNA found in a blood sample is correlated to the tumor size; at early
stages, when the tumor is small, the percentage of ctDNA present in the blood will be limited
(Stewart et al., 2018). In early stage cancer, ctDNA can make up only 1% of cfDNA but that can
increase to 40% in late stage cancer (Neumann et al., 2018). There are also limitations with the
inability of liquid biopsy to determine the location of origin of the cancer (Cohen et al., 2018).
Psychosocial considerations
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While there is limited data on the psychosocial impact of using ctDNA and liquid biopsy
for cancer screening, there is significant evidence of the negative effect of other screening
methods when false positive results are the outcome (Brodersen & Siersma, 2013; Lipkus et al.,
2000; Toft et al., 2019). As part of understanding the clinical utility of ctDNA for screening, is a
need for research into the psychosocial implications of screening. It is reasonable to suspect that
different psychosocial effects may be present that are not seen in other screening methods. This
is due to the limitation of liquid biopsy not being able to determine the location of origin of the
cancer and the often further advanced stage of cancer that ctDNA is able to be detected. Further
research into these areas could shed more light onto the utility and impact of this cancer
detection technology.
MATERIALS AND METHODS
Sample Population
Study participants were recruited from among participants in Geisinger’s DETECT
(Detecting Cancers Earlier Through Elective Mutation-Based Blood Collection and Testing)
research study. Inclusion criteria for DETECT study participants included women, ranging in age
from 65-76, with no prior personal history of cancer. Of the DETECT participants, 97% are of
Caucasian ancestry. Participants were from within the Geisinger catchment area, which covers
central Pennsylvania.
Within the DETECT study, participants initially gave six tubes of blood. ctDNA and
cancer biomarkers were analyzed using a “research marker panel test,” called CancerSEEK.
Participants in the DETECT study who received two consecutive positive blood test results were
contacted by the DETECT study genetic counselor with the result disclosure and
recommendation to have a follow-up PET-CT. Following the PET-CT, patient results were
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disclosed by a DETECT study physician, either an oncologist or primary care physician (A. M.
Lennon et al., 2020). DETECT study participants who opted to undergo a PET-CT scan were
eligible for participation in this qualitative study. A list of DETECT participants who had a PETCT was provided by the DETECT research study team.
Procedures
The DETECT study used the CancerSEEK blood test to interrogate the blood samples,
from each participant, for 16 genes associated with cancer and levels of 11 protein markers, that
can be elevated in individuals with cancer. CancerSEEK is expected to detect multiple cancer
types, including pancreatic, ovarian, esophageal, liver, lung, breast, colorectal and stomach
cancer. Participants were informed that their results might be used for research purposes beyond
the DETECT research study.
Qualitative interviews, using an investigator-created interview guide informed by
previous research on psychosocial outcomes of cancer screening tests, were conducted with
eligible participants to assess psychosocial outcomes of having a positive ctDNA test. The
interview guide began with general consent for participation, as well as consent for audio
recording, and usage of data for research purposes in accordance with the study IRB. Interviews
were conducted until saturation of responses was reached. There were five attempts to reach
eligible participants before they were excluded from the study. Participant data were deidentified and stored with each participant interview case number for reference. All participant
transcripts and audio recordings were saved on a Geisinger-protected desktop and were uploaded
into the qualitative analysis program Atlas.ti. Qualitative analysis was conducted to assess
participant views and psychosocial outcomes associated with a ctDNA-based cancer screening
test. This study received an exemption from the Sarah Lawrence College Institutional Review
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Board (IRB) in October 2019 along with approval from the Geisinger Health System IRB in
April 2019.
Measures
The qualitative interview guide consisted of 9 stem questions, each followed by 0-10
probes to obtain additional nuance. Stem questions were aimed at assessing participants’
rationale for joining the study, initial concerns regarding the possibility of detecting cancer,
emotional response and coping strategies after the results of the CancerSEEK blood test and
PET-CT scan, as well as response to discordant results (i.e., positive CancerSEEK followed by
negative PET-CT), when applicable, previous cancer screening medical behaviors, and overall
DETECT study satisfaction. Probe questions were aimed at gaining a better understanding of
how participants coped with results, the negative and positive psychosocial outcomes they
experienced, and their perception on the utility of the CancerSEEK blood test. Each participant
was asked the 9 stem questions; probes were asked at the discretion of the interviewer based on
the need for deeper or more comprehensive reflection.
Analysis
The codebook was created with the goal of identifying psychosocial themes that may
have been present during the participants’ contemplation of DETECT study participation,
discovery of the CancerSEEK blood test results, discovery of PET-CT results, and post PET-CT
experience. Themes and ideas stated in the interviews were identified as codes for the codebook.
Codes were contributed by both study coders to capture the full range of psychosocial themes
and emotions described by study participants. The codes are organized by major themes (Table
1) which allowed the coders to capture data relating to the most relevant psychosocial
experiences expressed throughout the study. The codebook was established by consensus and
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reviewed by the research supervisor. The final codebook contained 76 codes (Appendix B).
Inclusion criteria were defined for each code to maintain consistency in applying the codebook to
the interviews.

Complete List of 16 Major Themes
Theme Number

Major Themes

1

Awareness of Study Purpose

2

Rationale for Participation

3

Baseline Cancer Concern

4

CancerSEEK Emotional Reaction

5

CancerSEEK Coping

6

CancerSEEK Process Issue

7

PET-CT Emotional Reaction

8

PET-CT Process Issue

9

PET-CT Incidental Findings

10

PET-CT Understanding

11

PET-CT Coping

12

Emotional Reaction to Discordant Results

16

13

Coping with Discordant Results

14

Post Results Emotional Response

15

Previous Cancer Screening (Medical Behavior)

16

Study Satisfaction

Table 1. Complete List of 16 Major Themes.

Software analysis processing issues with Atlas.ti hindered the ability to establish interrater reliability between both coders. Atlas.ti was able to recognize that two individuals were
coding separately; however, after running an analysis, the software counted the codes as one
rather than two separate responses. This method would have hindered the overall data analysis;
therefore, the coders addressed this issue through consensus coding.
Reliability of the codes was established through an iterative process. Both coders were
randomly given two interviews to code separately and then compared. This process was repeated
until both coders were consistently applying the appropriate codes to the themes found in the
interviews. Once sufficient agreement on the usage of codes was reached, all 36 interviews were
assessed by both coders together through consensus coding. Interviews were coded at the group
level, with the intent to capture responses in both the negative and positive PET-CT groups. If a
participant expressed similar statements multiple times throughout a transcript, the responses
were repeatedly coded to collectively capture the psychosocial outcomes.
For the analysis of this study, participants with a negative PET-CT scan for cancer and a
positive PET-CT scan for cancer were analyzed separately before being compared. Interviews
from participants in both groups were analyzed for thematic content related to psychosocial
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outcomes associated with the DETECT study. Comparisons using Atlas.ti were performed
between and among participants in the positive and negative PET-CT groups.
Before analysis began, the data were normalized to account for differences in interviews
of the negative and positive PET-CT participants. More negative PET-CT interviews were
conducted and the number of coded statements in these interviews was greater than in the
positive PET-CT interviews. Therefore, code percentages of the positive PET-CTs were
normalized to account for the difference. The coding percentages for the positive PET-CT
interviews were multiplied by 1.12, the quotient of the number of negative PET-CT and positive
PET-CT interviews, 19/17= 1.12.
Once all interviews were coded, an analysis was run using the “Code Document Table”
and “Code Co-Occurrence Tree” functions. The results represent significant findings outlined
within the 16 major themes featured throughout the study, all of which highlight psychosocial
outcomes associated with a ctDNA-based cancer screening test.
RESULTS
Participants
Eligible participants consisted of 21 individuals with negative follow-up PET-CT scan
results, of which 19 participated, and 23 individuals with positive follow-up PET-CT scan
results, of which 17 participated, an overall response rate of 82%. All of the positive PET-CT
scan interview participants were diagnosed with cancer. Of the eligible women from the
DETECT study, 3 declined to participate, 1 passed from cancer, 3 could not be reached after five
phone call attempts and 1 was excluded due to inability to remember participation in the
DETECT study. Of the study participants, 97% identified as Caucasian. A total of 36 participant
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interviews were included in the study and subsequently analyzed for psychosocial outcomes
associated with a ctDNA-based cancer screening test.
Code Document Table Results
Awareness of Study Purpose
In comparing DETECT study awareness among participants, women with negative PETCTs were more likely to be aware of the study purpose and less likely to be uninformed of the
study purpose as compared to women with positive PET-CTs (Figure 1).

Figure 1. Study awareness among participants. Abbreviations: Gr=Groundedness of Codes (number of quotations
attributed to a code), GS= Number of documents in a document group

Rationale for Participation
In regard to rationale for participation in DETECT among study participants, 40% of the
overall responses among participants in both groups were coded as altruism. There was no
significant difference between participants in the negative and positive PET-CT groups. Both
envisioned their participation to be able to help future generations. Also expressed in about one-
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quarter of responses, in both groups, was a desire to participate because of a family history of
cancer and a desire to gain more personal health information for personal utility.
“In order for science or whatever to advance to help people, somebody has to volunteer, and
I’m glad for other medicines that come up through studies, that I thought well maybe I should
be the one this time to do the study.” (Negative PET-CT: Altruism)
“Well, I figured that if I could help anyone it would be a plus for people everywhere.”
(Positive PET-CT: Altruism)

Baseline Cancer Concern
Among women in the negative PET-CT interview group, the most commonly reported
emotional response related to “the possibility that the test would lead to finding cancer” was
acceptance at 46%. This is compared to 50% of responses in the positive PET-CT interview
group that were unprepared for the possibility that testing would lead to a cancer diagnosis.
“Cancer was the farthest thing from my mind.” (Positive PET-CT: Unprepared)
“I didn’t think I had any possibility of having any cancer.” (Positive PET-CT: Unprepared)

CancerSEEK Emotional Reaction, Process Issues, and Coping
Participants mainly reported feelings of surprise and being upset in response to
CancerSEEK. Participants reported confiding in someone after receiving their CancerSEEK
blood test result. In both groups, some participants were dissatisfied with the timing and
communication of study results.
In the positive PET-CT group, 33% of responses expressed being surprised by the results
of the CancerSEEK blood test. The most prevalent emotional reaction for the negative PET-CT
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group were feelings of being upset by the abnormal blood test, which was shared among 20% of
the overall responses. Of note, 10% of participant responses in the negative PET-CT group
emphasized feelings of being scared after receiving the CancerSEEK blood test result; however,
this emotion was not expressed by any participants in the positive PET-CT group.
Dissatisfaction with timing and communication of DETECT study results was a logistical
process issue associated with the CancerSEEK blood test. Eight responses by participants in the
negative PET-CT group and five responses made by participants in the positive PET-CT group
emphasized these challenges.
“I wish that [it] could be a shorter period of time so you’re not worrying for weeks and weeks
about it.” (Negative PET-CT: Dissatisfaction)
“I would think they should be able to process it faster,” (Positive PET-CT: Dissatisfaction)

In regard to coping with the CancerSEEK blood test results, the most prevalent response
was confiding with family members or close friends. Confiding accounted for 53% of negative
PET-CTs interview responses and 68% of positive PET-CT interview responses. Of note, 17% of
negative PET-CT responses for coping expressed relying on the DETECT genetic counselor for
support; in comparison to positive PET-CT responses with 9%.
“I talked to a couple of close friends, my husband, my son and daughter… I told them I was
concerned about it” (Negative PET-CT: Coping - Confiding)
“My significant [other] and my son I did tell, but they were real supportive.” (Positive PETCT: Coping - Confiding)
“The counselor, he was very, very helpful and he assured me that, it does not mean I have
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cancer. ” (Negative PET-CT: Coping - GC)
“The genetic counselor that called me explained and answered all of my questions, so that
was good.” (Positive PET-CT: Coping - GC)

Figure 2. CancerSEEK coping strategies among participants. Abbreviations: Gr=Groundedness of Codes
(number of quotations attributed to a code), GS= Number of documents in a document group

PET-CT Emotional Reaction, Process Issues, and Coping
As with responses to abnormal CancerSEEK blood test results, participants in both
interview groups coped with the PET-CT results by confiding in others. Of note, the majority of
positive PET-CT participants reported feeling confused by their results due to unclear result
disclosure.
Similarly to the CancerSEEK blood test responses, the most common form of coping
within the positive PET-CT interview group was confiding in family members or close friends,
representing 36% of responses. For the negative PET-CT interview group responses, the most
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common emotional reaction was anxiety, characterized by 36% of responses. Whereas for
positive PET-CT responses, the most common emotional reaction was acceptance, characterized
by 26% of responses.
Sixty percent of positive PET-CT interview responses described participants being
confused by their results. This confusion was due to participants feeling inadequately informed
of their results and being overwhelmed by the presented medical language, due to lack of clear
result disclosure by the clinician. In addition to unclear results, 26% of responses expressed
dissatisfaction with the timing of result disclosure. Significantly fewer responses in the negative
PET-CTs interviews, 10%, expressed confusion regarding results. However, significantly more
of these responses highlight dissatisfaction with the timing of the PET-CT.
“I have no clarity. I don’t know anything about what this now means, my odds of having
cancer are or aren’t, and what I might need to be doing other than having the test again.”
(Positive PET-CT: Confusing Results)
“I couldn’t decipher it all because of course it’s in medical talk.” (Positive PET-CT:
Confusing Results)
“That’s really scary when you’re waiting 5 and 6 weeks to find out what’s going on. I just had
to say that. That would be my only complaint.” (Negative PET-CT: Dissatisfaction)
“They really need to speed this up because it’s just absolutely torture when you know there’s
something wrong.” (Positive PET-CT: Dissatisfaction)

Psychosocial Reaction to Discordant CancerSEEK Results and PET-CT Findings
A crucial point of analysis is the psychosocial impact of discordant results for women
with a false positive CancerSEEK blood test (i.e., positive CancerSEEK with subsequent
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negative PET-CT scan). For women in the negative PET-CT group, 47% of responses expressed
relief regarding the non-cancer incidental findings. Another 35% expressed neutral responses, in
that they had no strong feelings about the non-cancer incidental findings. In comparing how
women with discordant results coped, 88% of responses stated they confided in someone upon
receiving the negative PET-CT scan result; while 11% of responses were in reference to relying
on faith. While being found to be negative for a malignancy, 11 women in the negative PET-CT
interview group had medically relevant non-cancer incidental findings reported from the PETCT scan (e.g., hepatic cysts, pulmonary nodules, thyroid nodules, lung disease, and pericardial
effusion). Of the six mentions of non-cancer incidental findings among the negative PET-CT
interview group, five expressed responses of positive emotion regarding the findings.
“I felt that was OK, you know. Apparently something triggered it, and I’m glad they pursued it
to make sure everything was OK.” (Negative PET-CT: Relief)
“I’m glad the CT scan didn’t show any tumors at the time.” (Negative PET-CT: Relief)
“I just didn’t get too concerned about it.” (Negative PET-CT: Neutral)
“I just felt these things happen. I didn’t feel anything different one way or the other.”
(Negative PET-CT: Neutral)
“I just relied on my faith that is all.” (Negative PET-CT: Faith)
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Figure 3. Emotional reaction to discordant results Negative PET-CT participants. Abbreviations:
Gr=Groundedness of Codes (number of quotations attributed to a code), GS= Number of documents in a document
group

Study Satisfaction
The majority of study participant responses in the negative and positive PET-CT
interview groups expressed that they would recommend the study to others and supported the
idea of using the CancerSEEK blood test in routine care. Although anxiety was noted in both
groups throughout the process, many commented on their appreciation and gratefulness for the
DETECT study.
The overwhelming majority of participants expressed responses supporting the use of the
CancerSEEK blood test in routine care; this sentiment was shared among 94% of responses in
the negative PET-CT group and 88% of responses in the positive PET-CT group. Remaining
responses expressed feelings of the DETECT study not yet being ready for use in routine care.
Similar responses were shared in regard to participants' feelings of whether they would
recommend the DETECT study to others; this consisted of 100% of responses in the negative
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PET-CT interview group and 94% of responses in the positive PET-CT interview group. Only
one response in the positive PET-CT interview group felt they would not recommend the study
to others. In regard to the overall DETECT study, 20% of positive PET-CT participants (n=3)
stated that they had a negative DETECT experience. Furthermore, 100% (n=19) of negative
PET-CT interview participants and 80% (n=14) of positive PET-CT interview participants
shared that they had a positive DETECT experience.
Some participants made suggestions as to what would make the DETECT study most
useful in everyday care. Of these stipulations, cost was a major factor for participants in the
positive PET-CT interview group. Twenty-three percent of responses emphasized that the
CancerSEEK blood test should be available if it is financially accessible. As well as cost, 33%
and 15% of negative and positive PET-CT interview responses, respectively, expressed feelings
that males should be included in the study to have the best impact. The last criteria for inclusion
participants expressed was that only individuals with a personal or family history should use the
test in everyday care. This sentiment was expressed by 22% of negative PET-CT interview
responses compared to 8% of positive PET-CT interview responses.
“Broaden the study to include not just females but males,” (Negative PET-CT: Include males)
“If it is affordable. I don’t know what the cost is, but it is probably expensive and people who
don’t have insurance probably, you know, couldn’t do it.” (Positive PET-CT: Cost)
“I think if people have history, family history of it, it would be good for them.” (Positive PETCT: Family history)

Regarding participants' emotional reactions to DETECT study satisfaction, in positive
PET-CT participant interviews, 52% of responses expressed a sense of appreciation and
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gratefulness for the DETECT study; in comparison to negative PET-CT participant interview
responses accounting for 24%. Pertaining to negative psychosocial outcomes, 11% of positive
PET-CT interview responses and 35% of negative PET-CT interview responses reported feelings
of anxiety throughout the DETECT study. Of note, an important finding from our analysis
showed that only positive PET-CT participant interview responses expressed feelings of trauma
or being upset regarding study satisfaction, representing 7% in both categories.

Figure 4. Emotional responses regarding study satisfaction among participants. Abbreviations:
Gr=Groundedness of Codes (number of quotations attributed to a code), GS= Number of documents in a document
group

“To me, it was a wonderful experience and I was glad to know that if something had come up
and I would have had to deal with a life or death situation that I wouldn’t stress out about it.”
(Negative PET-CT: Positive DETECT Experience)
“I’m grateful something was found and that it didn’t take long to schedule then, the further
studies, and to move on with a plan.” (Positive PET-CT: Positive DETECT Experience)
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“I’m so grateful to be part of that program and the whole procedure, I’m just very, very
grateful. It’s something I would have never known about.” (Negative PET-CT:
Grateful/Appreciation)
“I am grateful that DETECT was there and asked me to participate in this program, because I
found nothing.” (Positive PET-CT: Grateful/Appreciation)

DISCUSSION
This qualitative study was performed with the purpose of understanding the psychosocial
outcomes associated with abnormal ctDNA testing to better understand how it could positively
or negatively impact patient care. The research performed in this study analyzed participants’
emotional reactions and coping strategies, following DETECT study participation, through
qualitative analysis rather than quantitative measurement. To date, studies of ctDNA for cancer
detection have primarily been conducted using participants with a cancer diagnosis. The data
collected from the interviews in this study aids in future understanding of the benefits,
limitations, and usage of ctDNA-based screening tests in asymptomatic individuals.
Themes Shared Between Negative and Positive PET-CT Interview Groups
Between the negative and positive PET-CT interview groups, an overall response rate of
82% provides evidence of the findings being generalizable across DETECT participants.
The high percentage of responses supporting the use of the CancerSEEK blood test in
routine care and the recommendation of DETECT to others, is evidence of the general
acceptance of the DETECT study among participants, in both interview groups. In regard to
routine care, 94% of negative PET-CT and 88% of positive PET-CT responses support the usage
of the CancerSEEK blood test. This result gives support to the benefits of the CancerSEEK blood
test, outweighing any negative psychosocial outcomes experienced among participants in both
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groups. Regarding participants’ emotional responses to study satisfaction, both groups
emphasized finding value in having access to the information and of having a positive outcome
from participation in the study. This holds true for participants who were given discordant
CancerSEEK blood test results, suggesting that the discordant results and non-cancer incidental
findings may not have lasting negative psychosocial impacts.
While there were certainly positive psychosocial outcomes associated with the
CancerSEEK blood test found within the study, negative emotions were expressed by
participants regarding the DETECT study logistics. Both the negative and positive PET-CT
interview groups responses represented dissatisfaction with the timing and communication of the
DETECT study results for the CancerSEEK blood test. They had anticipated a shorter wait time
for return of results and were disappointed by the length of the process. Similar responses of
dissatisfaction with the timing of result disclosure were expressed regarding the PET-CT scan,
but a larger number of responses were reported as dissatisfaction with the timing of the PET-CT
scan procedure. These responses are understandable as women in the DETECT study waited
weeks to receive results for both the CancerSEEK blood test and PET-CT scan. Responses
emphasized additional complaints regarding the PET-CT scan procedure and the importance of
shortening wait times to allow for clear result disclosures in future trials of CancerSEEK.
Negative PET-CT Interview Themes
The negative PET-CT interview responses reported a higher percentage of study
awareness than those in the positive PET-CT interview group. This could be due to these women
being less overwhelmed by medical care following a cancer diagnosis, or to the anxiety of their
discordant results, making them hyper-aware of the study purpose. The retrospective nature of
the study likely created some bias in participant responses based on personal health outcomes,
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which could explain this result. Participant responses in this group reported feelings of
acceptance as their most common baseline concern for the possibility of the test detecting cancer.
Their retrospective acceptance is likely the result of knowing, at the time of the interview, that
they did not have cancer.
Feelings of being upset and scared were likely the most common emotional reaction to
the discordant CancerSEEK blood test because participants were not expecting to receive a
positive result. Regarding coping with discordant CancerSEEK blood test results, most responses
reported confiding in a family member or friends. However, responses relying on faith, confiding
in a GC, and confiding with a non-GC medical professional were all notably higher in the
negative PET-CT interview group than participants in the positive PET-CT interview group.
Regarding emotional responses to PET-CT results, it is understandable that the most
common reaction was nervousness or anxiety. Women in this group may have reported these
emotions because of the discrepancy between the discordant CancerSEEK blood test and PETCT results. However, this group expressed less confusion after they received their PET-CT scan
results which provided confirmation that they fully understood that they were not being
diagnosed with cancer. The women in this group were subsequently relieved or had no strong
feelings upon receiving discordant CancerSEEK blood test results and/or non-cancer incidental
findings. This could mean that there was not a lasting impact of negative psychosocial harms
following the discordant CancerSEEK blood test results. Notably, all but one of the women in
this group responded positively towards PET non-cancer incidental findings. This reaction
towards the PET-CT scan results showed that even if the PET-CT scan did not identify cancer,
they were grateful that it was capable of identifying other significant findings related to their
health.
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Every participant in the negative PET-CT interview group emphasized that they had an
overall positive DETECT experience. This identification of study satisfaction is helpful for
future expansion of the DETECT project. Responses in this group reported more feelings of
anxiety throughout the DETECT study. It is understandable that women in the negative PET-CT
group emphasized these responses because they received discordant results between the
CancerSEEK blood test and the PET-CT that led to excessive worry, whereas for the positive
group any worry would have been justified because they had cancer all along. To highlight
inclusion criteria, more responses in the negative PET-CT interview group expressed that only
individuals with a personal or family history of cancer should use the test in everyday care. This
response may be emphasizing that utilizing average-risk individuals in cancer screening studies
can result in negative psychosocial harms due to excessive worry.
Positive PET-CT Interview Themes
The increased lack of study awareness among women in the positive PET-CT interview
group was an interesting finding. These women may have been overwhelmed by the medical
care received after their cancer diagnosis, and less aware of the DETECT study as the reason for
that diagnosis. This was surprising given that cancer had been diagnosed through study
participation. It was assumed that more of these women would be aware of the DETECT study
purpose.
Again, the retrospective nature of the study and the final health outcome of a cancer
diagnosis may have created some recall bias among responses. In regard to baseline cancer
concern before starting the study, it is understandable that the majority of responses by women in
the positive PET-CT interview group had not considered the possibility of developing cancer.
Had these women not been diagnosed with cancer, it is possible that they, retrospectively, would
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have had more accepting responses towards that outcome. This sentiment is also seen in the
responses of women in this group towards the results of the CancerSEEK blood test. Women
were likely accepting of the result because with the benefit of hindsight they knew the results of
the CancerSEEK test to be true.
This study highlighted the importance of having a support system in place. Over half of
the responses to coping with results of the CancerSEEK blood test in the positive PET-CT group
expressed confiding in family or close friends; in addition, one-third of responses in this group
also expressed confiding as a way of coping with the results of the PET-CT scan. This shows that
like other cancer screenings, people want to share their results with those they are close to for
support. But it is interesting to note that many women in this group also internalized the results,
not wanting to share until they had more information. This could be the result of not having a
strong support system or needing confirmation before worrying others.
It is important to note the significant differences in responses in the positive PET-CT
interview group that expressed being confused by the results of their PET-CT scan compared to
those with negative PET-CT results. It is presumed that this confusion was due in part to
participants feeling inadequately informed of their results and being overwhelmed by the medical
language used. Clinicians can better communicate next steps, when a PET-CT is abnormal, by
disclosing results in-person and having a GC present to help define complicated medical
terminology. The presence of a GC would likely help alleviate the confusion and unclear results.
In addition to confusing results, responses expressed dissatisfaction with wait time for disclosure
of results; so much so that some women expressed discovering their cancer diagnosis by means
outside of the study. In thinking about the routine use of the CancerSEEK blood test and the
DETECT protocol, there is a need to address the time it takes for results to be released to patients
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as well as how these results are communicated. Hence, the next trial of the DETECT study
should help to address these issues.
It was postulated that there could be negative psychosocial outcomes for asymptomatic
women in the study to be diagnosed with cancer, but the lack of responses regarding feelings of
being upset or traumatized throughout study participation aids in disputing this thought. In
contrast, responses in the positive PET-CT interview group expressed more positive
psychosocial outcomes from study participation such as gratefulness and appreciation for being
in the study. Women were grateful and appreciated participating in the study despite lacking the
same level of study awareness of DETECT as participants in the negative PET-CT interview
group. Responses expressed feelings of finding value in the information, given that the
knowledge was used to make medically actionable decisions. It is reassuring for the possible
future use of the CancerSEEK blood test that, among responses in this group, there was
pervasive acceptance for routine use of the test and sentiments stating that participants would
recommend the study to others.
Study Limitations
While the study was designed to capture the range of psychosocial experiences and be
generalizable to larger populations, there are limitations of this study. While we maintain that the
sample size of the study was appropriate for the type of research performed, because a saturation
of themes was reached, studies in different populations (e.g., those with men or more racial
diversity) could present different psychosocial themes. Furthermore, the sample size consisted of
a comparison of responses for only two interview groups, the negative and positive PET-CTs for
cancer. Further research is warranted to investigate the psychosocial outcomes of individuals
with non-cancer incidental findings who are negative for cancer.
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It is recognized as a study limitation that the length of the DETECT study process likely
impacted recall, making it difficult for study participants to separate the CancerSEEK blood test
results from the abnormal, or normal PET-CT scan responses. Also, the retrospective design is a
limitation of the study. Participant responses were likely biased based on their personal health
outcomes in the study. A future study to address this limitation could be designed using a prepost test qualitative or quantitative approach, in which participants’ baseline psychosocial state
was captured prior to study intervention and diagnosis. Lastly, this study does not compare
psychosocial outcomes of ctDNA cancer screening to currently utilized screening methods. A
future study could compare outcomes in participants with discordant CancerSEEK blood test
results to those with discordant results from routine cancer screenings such as mammography.
CONCLUSIONS
The goal of our study was to assess psychosocial outcomes associated with a ctDNA-based
cancer screening test, by questioning whether the CancerSEEK blood test was acceptable to
women with an abnormal result. It is clear from our analysis that distinct similarities and
differences exist between the negative and positive PET-CT interview groups, highlighting the
psychosocial outcomes. The results that most significantly informed psychosocial outcomes of
CancerSEEK include:
1. Most notably, the majority of responses in both groups reported having a positive
experience with the DETECT study and would recommend it to others. This is especially
important to note for the negative PET-CT participants who received discordant
CancerSEEK blood test results.
2. Among all responses in both groups, confiding in family and friends was the most
commonly utilized coping strategy, following the results of the CancerSEEK blood test.
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This emphasized the importance of a sufficient support system being available following
screening.
3. For participants in the negative PET-CT group, who received non-cancer incidental
findings, the most prevalent emotional response was relief about the findings. While
anxiety was expressed regarding the false positive blood test, participants appreciated the
knowledge of the non-cancer incidental findings.
4. Among responses in both groups, there was expression of dissatisfaction with the
turnaround time for the CancerSEEK blood test and PET-CT results and the method in
which these results were communicated. Issues surrounding result disclosure was a
source of anxiety and concern based on study responses and needs to be further reviewed
for an effective screening protocol.
While this research is reassuring in providing evidence of the acceptability of the
CancerSEEK blood test as a screening method among those with an abnormal CancerSEEK
result, continued research should be explored to expand on these findings and identify additional
potential benefits of ctDNA testing. It is the hope that one day, a ctDNA cancer screen will be
implemented for early detection of cancer, particularly for those cancers without valid screening
modalities in place.
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Appendix A
Qualitative Interview Guide
[Introduction Script] Hello, Ms._______. My name is Gabby/Simone and I’m a Genetic
Counseling Student working with Geisinger Health System. I am calling about the DETECT
study that you are part of. We would like to know more about your experiences with the study.
Would you be interested in answering some questions about your participation in the study?
[If no] Is there another time you would be available and interested in participating?
[If yes, discuss new time for interview and plan to re-contact the patient.]
[If no] Thank you for your time and thanks again for being in DETECT.
[If yes] These questions should take up to 15-20 minutes. Do you have time to answer them
now?
[If yes] Thank you. Before we start, here are a couple of things to know about this interview. We
are interviewing DETECT participants who had an abnormal result on the DETECT blood test.
Your responses will help us learn more about what it is like to receive a result like yours. I will
ask you some broad questions and then follow-up with some more specific questions about your
experience with receiving results from the DETECT study. You can say whatever you want –
nothing will hurt my feelings and nothing you say will have a negative effect on your care.
Everything you tell me will be kept confidential. Your interview responses will only be shared
with research team members and nothing will identify you if the information you share is used
for future reports on the findings from this study. Participation in this interview is voluntary and
you can stop at any time. Please remember: be honest with your responses and you do not have
to answer anything you do not want to talk about. You can end the interview at any time. If you
have any questions you can ask us during the interview or contact us afterwards at the following
phone numbers: (570) 301-3014 or (336) 254-8378. Do you have any questions about this
interview? Do you agree to participate in this study?
[If yes to participation] Before we begin, would you mind if I recorded this conversation so that
I make sure I don’t miss anything that you tell me? We will remove your name and any
identifying information from the recording. Some of this information will be stored in a research
record at Geisinger and they can be kept for up to 3 years.
[If no to participation] Thank you for your time and thanks again for being in DETECT.
[If no to recording] Okay, that’s fine. I may need a little bit of extra time to make sure I write
down what you tell me as completely as possible.
1) Do you remember why the DETECT study is being done?
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[If yes] Can you tell me in your own words why they are doing the DETECT study?
[If no] The DETECT study uses a blood sample to look for cancer markers, either DNA from a
tumor or elevated levels of proteins. You may recall having your blood drawn after consenting
to be part of the project. The purpose of the DETECT study is to learn how well the blood test
works at finding cancer early.
2) What motivated you to want to join the study?
1. Probe (if applies): What did you hope to get from being in the study?
2. Probe (if applies): Some participants expressed that they have a strong family history of
cancer and maybe by participating in this study they might better understand their own cancer
risk. Was this the case for you?
3. Probe: Others my may want to help further scientific research and see if this technology
can be helpful to future generations. Was this the case for you?
4. Probe (if applies): *If more than one motivation listed ask* “which one influenced you
the most?”
3) When you joined the study, how did you feel about the possibility that the test would lead to
finding cancer?
Narrative: We know that when someone is diagnosed with cancer, genetic material known
as DNA is shed into their bloodstream. This specific type of genetic material is called
circulating tumor DNA or ctDNA. As you recall, ctDNA or biomarkers looking for these
specific cancers were detected in your bloodstream when we looked at your sample. This
result did not necessarily mean that you had cancer, so the study team recommended that
you have additional testing with a PET-CT scan.
4) How did you feel when the blood work results were abnormal indicating the possible presence
of cancer?
1. Probe (if applies): Was this type of result something you were expecting?
2. Probe (if applies): Emotionally and psychologically, what did you experience after
getting these results?
3. Probe: How did you feel about being asked to have a PET-CT scan?
4. Probe (if applies): Who did you lean on and communicate these results to?
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5. Probe: Did you find that you needed more support than expected after receiving the
results?
5) (For abnormal PET-CT scan) What do you remember about the results of the PET-CT scan?
1. Probe (if applies): What did you do medically to follow-up on the scan?
2. Probe (if applies): How did you feel about the results of the PET-CT scan?
3. Probe (if applies): Was this type of result something you were expecting?
4. Probe (if applies): Emotionally and psychologically, what did you experience after
getting these results?
5. Probe (if applies): How are you dealing with a cancer diagnosis?
6. Probe (if applies): Does this result change any future management for you going
forward?
7. Probe (if applies): Who did you communicate these results to?
8. Probe (if applies): Who did you lean on for emotional support?
9. Probe (if applies): Did you need more support than expected?
6) (For normal PET-CT scan) What do you remember about the results of the PET-CT scan?
1. Probe (if applies): What did you do medically to follow-up on the scan?
2. Probe (if applies): How did you feel about having an abnormal blood test but normal
PET-CT scan?
3. Probe (if applies): Was this type of result something you were expecting?
4. Probe (if applies): Emotionally and psychologically, what did you experience after
getting these results?
5. Probe (if applies): Who did you communicate these results to?
6. Probe (if applies): Who did you lean on for emotional support?
7. Probe (if applies): Did you need more support than expected?
7) How have your feelings toward the DETECT study changed since you received your PET-CT
scan results?
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1. Probe (if applies): [If yes] How?
2. Probe (if applies): [If no] Can you tell me more about why you did not feel any
different about the DETECT study?
3. Probe: Would you recommend to friends or family members that they join DETECT?
8) How did cancer screening in this study compare to other cancer screening you have done?
1. Probe (if applies): What cancer screening do you routinely have?
9) What are your thoughts on whether the DETECT blood test should be part of everyday care?
1. Probe (if test should be part of everyday care): Before the test were offered in
everyday care, what would you change about how the test is performed or followed up on?
2. Probe (if not ready for everyday care): What else needs to be done or studied before
the test is ready for everyday care?
10) What other psychological, emotional or social outcomes from your participation in the study
would you like to share?
Conclusion: Those are all of the questions I have. Thank you for your participation in this
interview. I appreciate your time and responses. Your answers will help to better understand the
expectations and experiences of study participants and may help improve how to better
understand DETECT study results. Your responses will remain confidential. If you have any
additional questions, please do not hesitate to contact us. Hope you have a wonderful day!
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Appendix B
The Complete List of 76 Codes
Code Number

Major Themes - Code

Definition/Inclusion Criteria

1

Awareness of Study Purpose Knowledgeable

Participant was actively able to recognize the
purpose of the DETECT study

2

Awareness of Study PurposeUninformed

Participant was not actively able to recognize the
purpose of the DETECT study

3

Rationale for Participation - Altruism

Participant used statement of wanting to help others
and contribute to the current body of scientific
research, including early cancer detection

4

Rationale for Participation - Family
History

Participant used statement of family history of
cancer

5

Rationale for Participation - Personal
Utility

Participant wanted to know the information for their
own health; early detection

6

Rationale for Participation - Unsure

Participant was not aware of a specific reason for
enrollment

7

Rationale for Participation - Cure

Participant joined DETECT in the hope of finding a
cure for cancer

8

Baseline Cancer Concern - Unprepared

Participant did not think about the possibility of
cancer

9

Baseline Cancer Concern Unconcerned/Not worried

Participant was not concerned about the possible
thought of cancer

10

Baseline Cancer Concern - Acceptance

Participant applied statements of acceptance
regarding cancer recognition

11

Baseline Cancer Concern - Distress

Participant felt upset, nervous, or anxious regarding
the idea of cancer detection

12

Baseline Cancer Concern - Scared

Participant felt scared to learn about new
information regarding a potential cancer diagnosis
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13

CancerSEEK Emotional Reaction Anxiety

Use when participant verbalizes statements of
anxiety

14

CancerSEEK Emotional Reaction Upset

Use when participant verbalizes statements of being
upset

15

CancerSEEK Emotional Reaction Concern

Use when participant verbalizes statements of
concern

16

CancerSEEK Emotional Reaction Scared

Use when participant verbalizes statements of being
scared

17

CancerSEEK Emotional Reaction Acceptance

Use when participant verbalizes statements of
acceptance

18

CancerSEEK Emotional Reaction Confusion

Use when participant verbalizes statements of
confusion

19

CancerSEEK Emotional Reaction Surprise

Use when participant verbalizes statements of not
expecting result

20

CancerSEEK Emotional Reaction Not surprised/Not worried

Use when participant verbalizes that the results did
not have a significant impact on their quality of life

21

CancerSEEK Emotional Reaction Control group

Use when participant verbalizes belief that they
belonged to a different group within the study

22

CancerSEEK Coping - Internalized

Use when participant verbalizes that they dealt with
results alone; did not communicate

23

CancerSEEK Coping - Confiding

Use when participant verbalizes that they dealt with
result by confiding in someone

24

CancerSEEK Coping –
Genetic Counselor

Use when participant expresses communication,
reliance, or reassurance with a genetic counselor

25

CancerSEEK Coping – Non-GC
Medical Professional

Use when participant verbalizes concern with a
different medical professional other than a GC,
relied on gaining information and communicating a
with doctor
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26

CancerSEEK Coping Faith

Use when participant verbalizes that they relied on
faith and prayer

27

CancerSEEK Process Issue Dissatisfaction

Use when participant verbalizes statements of being
dissatisfied with timing of results for CancerSEEK

28

PET-CT Emotional Reaction - Upset

Participant expresses statements of feeling upset

29

PET-CT Emotional Reaction Concerned

Participant expresses statements of concern

30

PET-CT Emotional Reaction - Not
Concerned

Participant expresses statements of no concern

31

PET-CT Emotional Reaction Acceptance

Participant expresses statements of acceptance

32

PET-CT Emotional Reaction - Not
Expecting Results

Participant expresses statements of not expecting
results

33

PET-CT Emotional Reaction - Relief

Participant expresses relief after positive PET-CT
results

34

PET-CT Emotional Reaction Nervousness/Anxiety

Participant expresses statements of
nervousness/anxiety

35

PET-CT Process Issue - Dissatisfaction

Participant expresses statements of being
dissatisfied with the timing and communication of
results for the PET-CT scan

36

PET-CT Process Issue - PCP
Communication

Participant expresses problems reaching PCP after
disclosure of PET-CT results

37

PET-CT Non-Cancer Incidental
Findings - Positive Response to NonCancer Incidental Findings

Participant expresses positive emotion regarding
secondary findings

38

PET-CT Non-Cancer Incidental
Findings - Negative Response to NonCancer Incidental Findings

Participant expresses negative emotion regarding
secondary findings
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39

PET-CT Understanding - Confusing
Results

Participant expresses statements of lack of
understanding regarding the meaning of results

40

PET-CT Coping - Faith

Participant expresses they relied on faith and prayer

41

PET-CT Coping - Confiding

Use when participant verbalizes that they dealt with
result by confiding in someone

42

Emotional Reaction to Discordant
Results - Relief/Reassurance

Participant expresses relief after disclosure of
results

43

Emotional Reaction to Discordant
Results - Frustration

Participant expresses frustration that bloodwork was
abnormal and PET-CT was normal

44

Emotional Reaction to Discordant
Results - Concern

Participant expresses concern with the discordant
results

45

Emotional Reaction to Discordant
Results - Neutral

Participant expresses no strong emotions negatively
or positively

46

Coping with Discordant Results Confiding

Participant expresses that they dealt with discordant
results by confiding in someone

47

Coping with Discordant Results - Faith

Participant expresses coping with discordant results
by relying on faith and prayer

48

Post Results Emotional Response Scared

Participant expressed statements of being scared
following participation

49

Post Results Emotional Response Self-Guilt

Participant expressed statements of guilt for poor
personal habits

50

Post Results Emotional Response Importance of Medical Care

Participant expressed statements of being more
vigilant of medical needs/care

51

Previous Cancer Screening (Medical
Behavior) - Similar Screening
Comparison

Participant verbalized that previous cancer
screening is comparable to other cancer screenings
or no different
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52

Previous Cancer Screening (Medical
Behavior) - Different Screening
Comparison

Participant verbalized that previous cancer
screening is non-comparable to other cancer
screenings

53

Previous Cancer Screening (Medical
Behavior) - Ease of Process

Participant verbalized that the PET-CT and entire
DETECT process was easier than other screenings

54

Previous Cancer Screening (Medical
Behavior) - Inconvenient

Participant verbalized that cancer screening through
DETECT is inconvenient/time consuming than
other screenings

55

Previous Cancer Screening (Medical
Behavior) - Comprehensive

Participant verbalized that cancer screening through
DETECT is more in depth than other cancer
screenings

56

Study Satisfaction - Include Males

Participant felt the inclusion criteria should have
included males

57

Study Satisfaction - Personal/Family
History

Participant felt that the study is useful if participant
has an extensive medical/family history

58

Study Satisfaction - Cost

Participant verbalized that DETECT is useful if
offered at the appropriate cost

59

Study Satisfaction - Study Outcomes

Participant verbalized that DETECT is useful based
on overall study outcomes

60

Study Satisfaction - Prevention

Participant verbalized that DETECT is useful for
prevention

61

Study Satisfaction - Positive DETECT
Experience

Participant verbalized overall positive statements
towards DETECT and the study process

62

Study Satisfaction - Negative
DETECT Experience

Participant verbalized overall negative statements
towards DETECT and the study process

63

Study Satisfaction - Use in Routine
Care

Participant thinks DETECT should be used in
routine care

64

Study Satisfaction - Not used in
Routine Care

Participant does not think DETECT should be used
in routine care
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65

Study Satisfaction - Ease of Process

Participant felt the process for DETECT was easier
than other screenings/simple way to detect cancers
early

66

Study Satisfaction - Access to
Information

Participant valued having access to the information

67

Study Satisfaction - Anxiety

Participant felt that parts of the process caused
anxiety

68

Study Satisfaction - Upset

Participant verbalized statements of feeling upset

69

Study Satisfaction - Traumatic

Participant verbalized being emotionally
traumatized from the experience

70

Study Satisfaction - Change in
Feelings

Participant expressed change in attitude towards the
study

71

Study Satisfaction - No Change in
Feelings

Participant did not express change in attitude
towards the study

72

Study Satisfaction Grateful/Appreciation

Participant expressed statements of appreciation for
study and getting results

73

Study Satisfaction - Recommend to
Others

Participant would recommend the DETECT study
to others

74

Study Satisfaction - Not Recommend
to Others

Participant would not recommend the DETECT
study to others

75

Study Satisfaction - Positive Outcomes

Participant expressed statements of positive
experiences with medical professionals, rather than
experiences with the DETECT project

76

Study Satisfaction – Lack of Care

Participant expressed wanting more care post
getting results
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Appendix C
Complete list of codes and frequency of use in negative PET-CT group
Codes

Negative PET-CT
Interviews
Gr=348; GS=19
Tablerelative
Frequency

Absolute Frequency
● Awareness of study purpose - Knowledgeable
Gr=21
● Awareness of study purpose- Uninformed
Gr=15
● Baseline Cancer Concern - Acceptance
Gr=19
● Baseline Cancer Concern - Distress
Gr=2
● Baseline Cancer Concern - Scared
Gr=1
● Baseline Cancer Concern - Unconcerned/Not worried
Gr=8
● Baseline Cancer Concern - Unprepared
Gr=14
● CancerSEEK Coping - Confiding
Gr=31
● CancerSEEK Coping - Faith
Gr=6
● CancerSEEK Coping - GC
Gr=7
● CancerSEEK Coping - Internalized
Gr=4
● CancerSEEK Coping - non-GC Medical professional
Gr=4
● CancerSEEK emotional reaction - Acceptance
Gr=20
● CancerSEEK emotional reaction - Anxiety
Gr=6
● CancerSEEK emotional reaction - Concern
Gr=10
● CancerSEEK emotional reaction - Confusion
Gr=1
● CancerSEEK emotional reaction - Control group
Gr=1
● CancerSEEK emotional reaction - Not surprised/Not worried
Gr=6
● CancerSEEK emotional reaction - Scared
Gr=4
● CancerSEEK emotional reaction - Surprise
Gr=18
● CancerSEEK emotional reaction - Upset
Gr=10
● CancerSEEK Process Issue - Dissatisfaction
Gr=13

12

3.43%

7

2.00%

11

3.14%

2

0.57%

1

0.29%

6

1.71%

4

1.14%

16

4.57%

5

1.43%

5

1.43%

1

0.29%

3

0.86%

7

2.00%

5

1.43%

7

2.00%

0

0.00%

0

0.00%

3

0.86%

4

1.14%

6

1.71%

8

2.29%

8

2.29%
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● Coping with discordant results - Confiding
Gr=17
● Coping with discordant results - Faith
Gr=2
● Emotional reaction to discordant results - Concern
Gr=1
● Emotional reaction to discordant results - Frustration
Gr=2
● Emotional reaction to discordant results - Neutral
Gr=6
● Emotional reaction to discordant results - Relief/Reassurance
Gr=8
○ PET-CT coping - Confiding
Gr=11
● PET-CT Coping - Faith
Gr=3
● PET-CT emotional reaction - Acceptance
Gr=13
● PET-CT emotional reaction - Concerned
Gr=2
● PET-CT emotional reaction - Nervousness/anxiety
Gr=8
● PET-CT emotional reaction - Not concerned
Gr=6
● PET-CT emotional reaction - Not expecting results
Gr=3
○ PET-CT emotional reaction - Relief/Reassurance
Gr=3
● PET-CT emotional reaction - Upset
Gr=3
● PET-CT Process Issue - Dissatisfaction
Gr=17
● PET-CT Process Issue - PCP communication
Gr=7
● PET-CT Understanding - Confusing results
Gr=11
● PET-CT Non-Cancer incidental findings - Negative response to NonCancer incidental findings
Gr=1
● PET-CT Non-Cancer incidental findings - Positive response to Non-Cancer
incidental findings
Gr=5
● Post results emotional response - Importance of medical care
Gr=1
● Post results emotional response - Scared
Gr=1
● Post results emotional response - Self-guilt
Gr=2
● Previous Cancer Screening (Medical Behavior) - Comprehensive
Gr=8
● Previous Cancer Screening (Medical Behavior) - Different screening
comparison
Gr=6
● Previous Cancer Screening (Medical Behavior) - Ease of process
Gr=3

15

4.29%

2

0.57%

1

0.29%

2

0.57%

6

1.71%

8

2.29%

0

0.00%

3

0.86%

5

1.43%

2

0.57%

8

2.29%

3

0.86%

1

0.29%

0

0.00%

0

0.00%

13

3.71%

5

1.43%

2

0.57%

1

0.29%

5

1.43%

0

0.00%

0

0.00%

2

0.57%

2

0.57%

1

0.29%

1

0.29%
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● Previous Cancer Screening (Medical Behavior) - Inconvenient
Gr=4
● Previous Cancer Screening (Medical Behavior) - Similar screening
comparison
Gr=13
● Rationale for participation - Altruism
Gr=25
● Rationale for participation - Cure
Gr=3
● Rationale for participation - Family history
Gr=16
● Rationale for participation - Personal utility
Gr=14
● Rationale for participation - Unsure
Gr=5
● Study satisfaction - Study outcomes
Gr=1
● Study satisfaction - Anxiety
Gr=9
● Study satisfaction - Change in feelings
Gr=1
● Study satisfaction - Cost
Gr=3
● Study satisfaction - Ease of process
Gr=3
● Study satisfaction - Access to information
Gr=7
● Study satisfaction - Grateful/appreciation
Gr=18
● Study satisfaction - Include males
Gr=5
● Study satisfaction - Lack of care
Gr=3
● Study satisfaction - Negative DETECT experience
Gr=5
● Study satisfaction - No change in feelings
Gr=29
● Study satisfaction - Not recommend to others
Gr=1
● Study satisfaction - Not used in routine care
Gr=3
● Study satisfaction - Personal/family history
Gr=3
● Study satisfaction - Positive DETECT experience
Gr=33
● Study satisfaction - Positive outcomes
Gr=6
● Study satisfaction - Prevention
Gr=5
● Study satisfaction - Recommend to others
Gr=33
● Study satisfaction - Traumatic
Gr=2
● Study satisfaction - Upset
Gr=2

3

0.86%

10

2.86%

13

3.71%

3

0.86%

9

2.57%

7

2.00%

1

0.29%

1

0.29%

6

1.71%

1

0.29%

0

0.00%

0

0.00%

4

1.14%

4

1.14%

3

0.86%

0

0.00%

0

0.00%

20

5.71%

0

0.00%

1

0.29%

2

0.57%

13

3.71%

3

0.86%

4

1.14%

17

4.86%

0

0.00%

0

0.00%
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● Study satisfaction - Use in routine care
Gr=31
Totals

16

4.57%

350

100.00%
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Appendix D
Complete list of codes and frequency of use in positive PET-CT group
Codes

Positive PET-CT
Interviews
Gr=313; GS=17
Tablerelative
Frequency

Absolute Frequency
● Awareness of study purpose - Knowledgeable
Gr=21
● Awareness of study purpose- Uninformed
Gr=15
● Baseline Cancer Concern - Acceptance
Gr=19
● Baseline Cancer Concern - Distress
Gr=2
● Baseline Cancer Concern - Scared
Gr=1
● Baseline Cancer Concern - Unconcerned/Not worried
Gr=8
● Baseline Cancer Concern - Unprepared
Gr=14
● CancerSEEK Coping - Confiding
Gr=31
● CancerSEEK Coping - Faith
Gr=6
● CancerSEEK Coping - GC
Gr=7
● CancerSEEK Coping - Internalized
Gr=4
● CancerSEEK Coping - non-GC Medical professional
Gr=4
● CancerSEEK emotional reaction - Acceptance
Gr=20
● CancerSEEK emotional reaction - Anxiety
Gr=6
● CancerSEEK emotional reaction - Concern
Gr=10
● CancerSEEK emotional reaction - Confusion
Gr=1
● CancerSEEK emotional reaction - Control group
Gr=1
● CancerSEEK emotional reaction - Not surprised/Not worried
Gr=6
● CancerSEEK emotional reaction - Scared
Gr=4
● CancerSEEK emotional reaction - Surprise
Gr=18
● CancerSEEK emotional reaction - Upset
Gr=10
● CancerSEEK Process Issue - Dissatisfaction
Gr=13

9

2.96%

8

2.63%

8

2.63%

0

0.00%

0

0.00%

2

0.66%

10

3.29%

15

4.93%

1

0.33%

2

0.66%

3

0.99%

1

0.33%

13

4.28%

1

0.33%

3

0.99%

1

0.33%

1

0.33%

3

0.99%

0

0.00%

12

3.95%

2

0.66%

5

1.65%
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● Coping with discordant results - Confiding
Gr=17
● Coping with discordant results - Faith
Gr=2
● Emotional reaction to discordant results - Concern
Gr=1
● Emotional reaction to discordant results - Frustration
Gr=2
● Emotional reaction to discordant results - Neutral
Gr=6
● Emotional reaction to discordant results - Relief/Reassurance
Gr=8
○ PET-CT coping - Confiding
Gr=11
● PET-CT Coping - Faith
Gr=3
● PET-CT emotional reaction - Acceptance
Gr=13
● PET-CT emotional reaction - Concerned
Gr=2
● PET-CT emotional reaction - Nervousness/anxiety
Gr=8
● PET-CT emotional reaction - No recall of PET-CT
Gr=0
● PET-CT emotional reaction - Not concerned
Gr=6
● PET-CT emotional reaction - Not expecting results
Gr=3
○ PET-CT emotional reaction - Relief/Reassurance
Gr=3
● PET-CT emotional reaction - Upset
Gr=3
● PET-CT Process Issue - Dissatisfaction
Gr=17
● PET-CT Process Issue - PCP communication
Gr=7
● PET-CT Understanding - Confusing results
Gr=11
● PET-CT Non-Cancer incidental findings - Negative response to NonCancer incidental findings
Gr=1
● PET-CT Non-Cancer incidental findings - Positive response to Non-Cancer
incidental findings
Gr=5
● Post results emotional response - Importance of medical care
Gr=1
● Post results emotional response - Scared
Gr=1
● Post results emotional response - Self-guilt
Gr=2
● Previous Cancer Screening (Medical Behavior) - Comprehensive
Gr=8
● Previous Cancer Screening (Medical Behavior) - Different screening
comparison
Gr=6

2

0.66%

0

0.00%

0

0.00%

0

0.00%

0

0.00%

0

0.00%

11

3.62%

0

0.00%

8

2.63%

0

0.00%

0

0.00%

0

0.00%

3

0.99%

2

0.66%

3

0.99%

3

0.99%

4

1.32%

2

0.66%

9

2.96%

0

0.00%

0

0.00%

1

0.33%

1

0.33%

0

0.00%

6

1.97%

5

1.65%
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● Previous Cancer Screening (Medical Behavior) - Ease of process
Gr=3
● Previous Cancer Screening (Medical Behavior) - Inconvenient
Gr=4
● Previous Cancer Screening (Medical Behavior) - Similar screening
comparison
Gr=13
● Rationale for participation - Altruism
Gr=25
● Rationale for participation - Cure
Gr=3
● Rationale for participation - Family history
Gr=16
● Rationale for participation - For a lost friend or significant other
Gr=0
● Rationale for participation - Personal utility
Gr=14
● Rationale for participation - Unsure
Gr=5
● Study satisfaction - Study outcomes
Gr=1
● Study satisfaction - Anxiety
Gr=9
● Study satisfaction - Change in feelings
Gr=1
● Study satisfaction - Cost
Gr=3
● Study satisfaction - Ease of process
Gr=3
● Study satisfaction - Access to information
Gr=7
● Study satisfaction - Grateful/appreciation
Gr=18
● Study satisfaction - Include males
Gr=5
● Study satisfaction - Lack of care
Gr=3
● Study satisfaction - Negative DETECT experience
Gr=5
● Study satisfaction - No change in feelings
Gr=29
● Study satisfaction - Not recommend to others
Gr=1
● Study satisfaction - Not used in routine care
Gr=3
● Study satisfaction - Personal/family history
Gr=3
● Study satisfaction - Positive DETECT experience
Gr=33
● Study satisfaction - Positive outcomes
Gr=6
● Study satisfaction - Prevention
Gr=5
● Study satisfaction - Recommend to others
Gr=33

2

0.66%

1

0.33%

3

0.99%

12

3.95%

0

0.00%

7

2.30%

0

0.00%

7

2.30%

4

1.32%

0

0.00%

3

0.99%

0

0.00%

3

0.99%

3

0.99%

3

0.99%

14

4.61%

2

0.66%

3

0.99%

5

1.65%

9

2.96%

1

0.33%

2

0.66%

1

0.33%

20

6.58%

3

0.99%

1

0.33%

16

5.26%
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● Study satisfaction - Regrets participation
Gr=0
● Study satisfaction - Traumatic
Gr=2
● Study satisfaction - Upset
Gr=2
● Study satisfaction - Use in routine care
Gr=31
Totals

0

0.00%

2

0.66%

2

0.66%

15

4.93%

304

100.00%
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